Daily Digest: Cognitive Safety, End-of-Life Cannabis Access, and Regulatory Challenges — March 06, 2026
End-of-life cannabis access remains a critical issue for patients and healthcare providers. This digest highlights regulatory gaps and hospital policies impacting terminally ill patients. Cognitive safety in older adults using cannabis is also examined…
Daily Digest: Last 9 Hours: Cognitive Safety Data, End-of-Life Access, and Regulatory Friction — March 05, 2026
This digest highlights recent research on cognitive safety in older adults using cannabis, addressing dementia risk and clinical implications. It also covers advances in end-of-life cannabis access and ongoing regulatory friction. These insights provide…
Daily Digest: Last 24 Hours: Brain Aging, Driving Safety, and the Global Fight for Patient Access — March 05, 2026
Recent studies on cannabis cognitive aging older adults provide reassuring data about cognitive decline risks. Evidence shows THC blood levels poorly predict driving impairment. Patient access remains a critical issue in the U.S. and U.K. healthcare…
Daily Digest: Cannabis Impairment Testing, Brain Aging, and Evidence Race — March 05, 2026
The 2026 cannabis brain aging study highlights important neurobiological effects of regular cannabis use. This research provides critical insights into impairment testing challenges and clinical counseling. Clinicians should consider these findings when…
Daily Digest: Last 19 Hours: Aging Brains, Adolescent Risk, and the Slow March of Policy Reform — March 04, 2026
This digest reviews recent findings on cannabis and cognitive aging, highlighting reassuring safety data for older adults. It also addresses adolescent cannabis exposure risks and ongoing policy reform challenges. The focus on cannabis and cognitive…
Daily Digest: Last 48 Hours: Adolescent Risk, Aging Brains, and the Long Road to Pharmaceutical-Grade Cannabis — March 04, 2026
This digest highlights cannabis medicine maturity, focusing on age-stratified cannabis risks and recent advances. It covers cannabinoid hyperemesis syndrome and pharmaceutical-grade CBD development. The evolving regulatory landscape shapes clinical…
Daily Digest: Adolescent Risks and Pharmaceutical-Grade Cannabis Progress
This daily digest highlights pharmaceutical-grade CBD clinical trial development and adolescent cannabis exposure risks. Recent studies emphasize measurable harm from adolescent use. Meanwhile, cognitive aging research offers reassurance for older adults.
Daily Digest: Last 9 Hours: Cognitive Safety Signals, Adolescent Risk, and the Regulatory Puzzle That Still Defines Cannabis Medicine — March 03, 2026
This digest highlights age-dependent cannabis cognitive effects and their clinical implications. It addresses adolescent neurotoxicity risks and the regulatory puzzle that complicates cannabis medicine. The focus is on bridging clinical evidence with…
Daily Digest: Last 15 Hours: Pharmaceutical Standards, Cognitive Safety, and Policy Gaps — March 03, 2026
This digest highlights pharmaceutical standardization cannabinoid therapeutics as a key theme in recent cannabis research. It discusses clinical-grade cannabis and the gap between medicine and policy. The focus is on improving patient access through…
Daily Digest: Cannabis and Anxiety Risk in the Long Run — March 03, 2026
This digest reviews new cohort data on cannabis and anxiety risk long term. While cannabis may offer short-term relief, sustained use shows complex anxiety outcomes. Dr. Caplan provides clinical context on these findings.